Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center.

Savva C, Kaye P, Soomro I, Parsons SL, James E, Madhusudan S.

J Gastrointest Cancer. 2018 Mar;49(1):85-92. doi: 10.1007/s12029-017-0039-2. No abstract available.

PMID:
29230683
2.

Development of a telehealth monitoring service after colorectal surgery: A feasibility study.

Bragg DD, Edis H, Clark S, Parsons SL, Perumpalath B, Lobo DN, Maxwell-Armstrong CA.

World J Gastrointest Surg. 2017 Sep 27;9(9):193-199. doi: 10.4240/wjgs.v9.i9.193.

3.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Br J Surg. 2017 Dec;104(13):1816-1828. doi: 10.1002/bjs.10627. Epub 2017 Sep 25.

4.

The front-line general surgery consultant as a new model of emergency care.

Navarro AP, Hardy E, Oakley B, Mohamed E, Welch NT, Parsons SL.

Ann R Coll Surg Engl. 2017 Sep;99(7):550-554. doi: 10.1308/rcsann.2017.0081. Epub 2017 Jul 6.

5.

Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.

Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, Welch NT, Madhusudan S, Parsons SL.

Ann R Coll Surg Engl. 2017 May;99(5):378-384. doi: 10.1308/rcsann.2017.0024.

6.

The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.

Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, Soomro I, Kaye P, Madhusudan S, Parsons SL.

J Surg Oncol. 2017 Jun;115(7):821-829. doi: 10.1002/jso.24601. Epub 2017 Mar 2.

PMID:
28257148
7.

Individual patient oesophageal cancer 3D models for tailored treatment.

Saunders JH, Onion D, Collier P, Dorrington MS, Argent RH, Clarke PA, Reece-Smith AM, Parsons SL, Grabowska AM.

Oncotarget. 2017 Apr 11;8(15):24224-24236. doi: 10.18632/oncotarget.12500.

8.

The relationship of plantar cutaneous sensation and standing balance post-stroke.

Parsons SL, Mansfield A, Inness EL, Patterson KK.

Top Stroke Rehabil. 2016 Oct;23(5):326-32. doi: 10.1080/10749357.2016.1162396. Epub 2016 Mar 31.

PMID:
27077993
9.

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.

Onion D, Argent RH, Reece-Smith AM, Craze ML, Pineda RG, Clarke PA, Ratan HL, Parsons SL, Lobo DN, Duffy JP, Atherton JC, McKenzie AJ, Kumari R, King P, Hall BM, Grabowska AM.

Mol Cancer Ther. 2016 Apr;15(4):753-63. doi: 10.1158/1535-7163.MCT-15-0598. Epub 2016 Feb 12.

10.

Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.

Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA.

Eur J Surg Oncol. 2015 Mar;41(3):333-8. doi: 10.1016/j.ejso.2014.11.040. Epub 2014 Nov 26.

PMID:
25498359
11.

The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.

Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M.

Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8.

12.

Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication.

Perry C, Soomro I, Kaye P, Hardy E, Parsons SL, Ragunath K, Lobo DN, Martin SG, Madhusudan S.

Dis Esophagus. 2015 Apr;28(3):262-8. doi: 10.1111/dote.12190. Epub 2014 Feb 24.

PMID:
24612464
13.

British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J; British Society of Gastroenterology.

Gut. 2014 Jan;63(1):7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.

PMID:
24165758
14.

Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma.

Woolston CM, Madhusudan S, Soomro IN, Lobo DN, Reece-Smith AM, Parsons SL, Martin SG.

Redox Biol. 2013 May 23;1:285-91. doi: 10.1016/j.redox.2013.04.006. eCollection 2013.

15.

Reduction in length of stay for patients undergoing oesophageal and gastric resections with implementation of enhanced recovery packages.

Tang J, Humes DJ, Gemmil E, Welch NT, Parsons SL, Catton JA.

Ann R Coll Surg Engl. 2013 Jul;95(5):323-8. doi: 10.1308/003588413X13629960046039.

16.

Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.

Khanna A, Reece-Smith AM, Cunnell M, Madhusudan S, Thomas A, Bowrey DJ, Parsons SL.

Dis Esophagus. 2014 Apr;27(3):242-7. doi: 10.1111/dote.12084. Epub 2013 May 7.

PMID:
23651074
17.

Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas.

Storr SJ, Pu X, Davis J, Lobo D, Reece-Smith AM, Parsons SL, Madhusudan S, Martin SG.

J Gastroenterol. 2013 Nov;48(11):1213-21. doi: 10.1007/s00535-012-0743-4. Epub 2013 Jan 19.

PMID:
23329366
18.

Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?

Abdel-Fatah T, Arora A, Gorguc I, Abbotts R, Beebeejaun S, Storr S, Mohan V, Hawkes C, Soomro I, Lobo DN, Parsons SL, Madhusudan S.

Antioxid Redox Signal. 2013 Jun 20;18(18):2392-8. doi: 10.1089/ars.2012.4873. Epub 2012 Oct 19.

PMID:
22894650
19.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL.

Ann Oncol. 2012 Aug;23(8):1979-85. doi: 10.1093/annonc/mds178. Epub 2012 Jun 24.

20.

MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas.

Reece-Smith AM, Saha S, Cunnell ML, Hameed K, Bessell EM, Duffy JP, Madhusudan S, Parsons SL.

J Surg Oncol. 2012 Nov;106(6):748-52. doi: 10.1002/jso.23187. Epub 2012 Jun 4.

PMID:
22674046
21.

Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.

Fareed KR, Soomro IN, Hameed K, Arora A, Lobo DN, Parsons SL, Madhusudan S.

World J Gastroenterol. 2012 Apr 28;18(16):1915-20. doi: 10.3748/wjg.v18.i16.1915.

22.

A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.

Reece-Smith AM, MacGoey P, Shah MA, Leeder P, Andrew DR, McCulloch T, Parsons SL.

Eur J Surg Oncol. 2012 Jun;38(6):484-9. doi: 10.1016/j.ejso.2012.01.011. Epub 2012 Feb 18.

PMID:
22342866
23.

Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer.

Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Parsons SL, Catton JA, Lobo DN.

Clin Nutr. 2012 Feb;31(1):74-7. doi: 10.1016/j.clnu.2011.08.008. Epub 2011 Aug 27.

PMID:
21875767
24.

Immunotherapy of peritoneal carcinomatosis with catumaxomab.

Parsons SL.

Onkologie. 2011;34(3):86-7. doi: 10.1159/000324793. Epub 2011 Feb 15. No abstract available.

25.

Novel staining pattern of p53 in Barrett's dysplasia--the absent pattern.

Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, Ilyas M.

Histopathology. 2010 Dec;57(6):933-5. doi: 10.1111/j.1365-2559.2010.03715.x. No abstract available.

PMID:
21166706
26.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL.

Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.

27.

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S.

Br J Cancer. 2010 May 25;102(11):1600-7. doi: 10.1038/sj.bjc.6605686. Epub 2010 May 11.

28.

Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.

Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, Madhusudan S.

Histopathology. 2009 Oct;55(4):399-406. doi: 10.1111/j.1365-2559.2009.03404.x.

PMID:
19817890
29.

Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.

Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, Faisal W, Catton J, Parsons SL, Ragunath K.

Histopathology. 2009 May;54(6):699-712. doi: 10.1111/j.1365-2559.2009.03288.x. Erratum in: Histopathology. 2009 Jun;54(7):917.

PMID:
19438745
30.

Biomarkers of response to therapy in oesophago-gastric cancer.

Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S.

Gut. 2009 Jan;58(1):127-43. doi: 10.1136/gut.2008.155861. Review.

PMID:
19091831
31.

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571).

Pinder EM, Atwal GS, Ayantunde AA, Khan S, Sokal M, McCulloch T, Parsons SL.

Sarcoma. 2007;2007:82012. doi: 10.1155/2007/82012.

32.

Analysis of blood transfusion predictors in patients undergoing elective oesophagectomy for cancer.

Ayantunde AA, Ng MY, Pal S, Welch NT, Parsons SL.

BMC Surg. 2008 Jan 25;8:3. doi: 10.1186/1471-2482-8-3.

33.

Esophagogastric cancers secondary to a breast primary tumor do not require resection.

Ayantunde AA, Agrawal A, Parsons SL, Welch NT.

World J Surg. 2007 Aug;31(8):1597-601. Review.

PMID:
17578645
34.

The role of staging laparoscopy in oesophagogastric cancers.

de Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT.

Eur J Surg Oncol. 2007 Oct;33(8):988-92. Epub 2007 Mar 7.

PMID:
17344017
35.

Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom).

Ahmed I, Welch NT, Parsons SL.

Eur J Surg Oncol. 2008 Apr;34(4):445-9. Epub 2007 Feb 21.

PMID:
17320340
36.

A survey of patient satisfaction and use of the Internet for health information.

Ayantunde AA, Welch NT, Parsons SL.

Int J Clin Pract. 2007 Mar;61(3):458-62.

PMID:
17313614
37.

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

Ayantunde AA, Parsons SL.

Ann Oncol. 2007 May;18(5):945-9. Epub 2007 Feb 13.

PMID:
17298959
38.

Early postoperative jejunostomy feeding with an immune modulating diet in patients undergoing resectional surgery for upper gastrointestinal cancer: a prospective, randomized, controlled, double-blind study.

Lobo DN, Williams RN, Welch NT, Aloysius MM, Nunes QM, Padmanabhan J, Crowe JR, Iftikhar SY, Parsons SL, Neal KR, Allison SP, Rowlands BJ.

Clin Nutr. 2006 Oct;25(5):716-26. Epub 2006 Jun 13.

PMID:
16777271
39.

Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.

Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA.

Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1.

PMID:
15993560
40.

Appendix mass: do we know how to treat it?

Ahmed I, Deakin D, Parsons SL.

Ann R Coll Surg Engl. 2005 May;87(3):191-5. Review.

41.

Declining mortality rate among people with diabetes in North Dakota, 1997-2002.

Tierney EF, Cadwell BL, Engelgau MM, Shireley L, Parsons SL, Moum K, Geiss LS.

Diabetes Care. 2004 Nov;27(11):2723-5. No abstract available.

PMID:
15505011
42.

Increasing rate of diabetes in pregnancy among American Indian and white mothers in Montana and North Dakota, 1989-2000.

Moum KR, Holzman GS, Harwell TS, Parsons SL, Adams SD, Oser CS, Spence MR, Helgerson SD, Gohdes D.

Matern Child Health J. 2004 Jun;8(2):71-6.

PMID:
15198174
43.

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer.

Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, Brown PD, Millar AW, Steele RJ, Parsons SL.

Eur J Cancer. 1999 Apr;35(4):563-8.

PMID:
10492628
44.

Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy.

Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ.

Br J Cancer. 1998 Dec;78(11):1495-502.

45.

Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.

Hutchinson JW, Tierney GM, Parsons SL, Davis TR.

J Bone Joint Surg Br. 1998 Sep;80(5):907-8.

PMID:
9768907
46.

Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.

Parsons SL, Watson SA, Steele RJ.

Eur J Surg Oncol. 1997 Dec;23(6):526-31.

PMID:
9484924
47.

Matrix metalloproteinases.

Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ.

Br J Surg. 1997 Feb;84(2):160-6. Review.

PMID:
9052425
48.

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.

Watson SA, Morris TM, Parsons SL, Steele RJ, Brown PD.

Br J Cancer. 1996 Nov;74(9):1354-8.

49.

Malignant ascites: a 2-year review from a teaching hospital.

Parsons SL, Lang MW, Steele RJ.

Eur J Surg Oncol. 1996 Jun;22(3):237-9.

PMID:
8654603
50.

Malignant ascites.

Parsons SL, Watson SA, Steele RJ.

Br J Surg. 1996 Jan;83(1):6-14. Review.

PMID:
8653366

Supplemental Content

Loading ...
Support Center